In vitro findings have established that ursodeoxycholic acid is a surrogate for deoxycholic
acid in preventing the growth of C. difficile, and interrupting recurrence. Investigators
will administer ursodeoxycholic acid for two months, beginning with Metronidazole and/or
Vancomycin (8 to 10 days), antibiotics currently used for the treatment of acute C.Difficile
infection. Ursodeoxycholic acid prevents c.difficile recurrence by (a) directly suppressing
the growth of C. Difficile and (b) permitting restoration of normal fecal bile acid
composition (80% deoxycholic acid) to maintain growth suppression.
Phase:
Phase 4
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health